Dr. Hisham Aljadhey, CEO of the Saudi Food and Drug Authority (SFDA), led a Saudi delegation to the annual summit of the International Coalition of Medicines Regulatory Authorities (ICMRA) held in Brasília, Brazil, from 12-13 November 2024. The participation underscores Saudi Arabia’s growing leadership in global health regulation and its commitment to international cooperation under the Kingdom’s Vision 2030.
Context and Background
The ICMRA summit brought together heads and representatives of 34 medicines regulatory agencies from around the world. This year’s summit focused on lessons learned from the COVID-19 pandemic and strategies for future preparedness. Dr. Aljadhey’s role as a panel moderator highlights the SFDA’s increasing influence and recognition on the global stage, particularly in promoting regulatory harmonization and protecting public health.
Key Details
Dr. Aljadhey moderated a high-level panel discussion on drug availability and regulatory challenges, alongside Dr. Yasuhiro Fujiwara, CEO of Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). The panel also included senior representatives from drug regulatory authorities in Australia, Brazil, and the United Kingdom. Discussions centered on ensuring drug effectiveness and safety, enhancing patient access to medicines, and balancing availability with rigorous safety standards. The summit also covered the ICMRA’s ongoing role in facilitating global regulatory convergence.
International Impact
This active participation strengthens the SFDA’s international standing and fosters collaboration with leading global regulatory bodies. By contributing to discussions on future global health emergencies, Saudi Arabia is positioning itself as a key partner in developing solutions for anticipated health challenges. The engagement further demonstrates the Kingdom’s commitment to public health and its alignment with best international practices, as outlined in the original report by the Saudi Press Agency (SPA).
Vision 2030 Alignment
SFDA’s leadership at the ICMRA summit directly supports Saudi Arabia’s Vision 2030 goals of enhancing the quality of life and building a vibrant society. By strengthening international partnerships and advancing regulatory science, the Kingdom is fostering a resilient health sector that can respond to future challenges effectively. This engagement reflects Saudi Arabia’s broader ambition to be a global leader in health regulation, innovation, and collaboration, ultimately contributing to a safer and more prosperous future for its citizens and the world.
20 Questions
Q1. What is the full name of the authority led by Dr. Hisham Aljadhey?
A1. Dr. Hisham Aljadhey is the CEO of the Saudi Food and Drug Authority (SFDA), which is responsible for regulating food, drugs, and medical devices in Saudi Arabia.
Q2. What summit did Dr. Aljadhey attend in November 2024?
A2. He attended the annual summit of the International Coalition of Medicines Regulatory Authorities (ICMRA), held in Brasília, Brazil from 12-13 November 2024.
Q3. Who co-moderated the panel discussion with Dr. Aljadhey?
A3. He co-moderated the session alongside Dr. Yasuhiro Fujiwara, the CEO of Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).
Q4. Which countries participated in the panel on drug availability?
A4. Representatives from drug regulatory authorities in Australia, Brazil, and the United Kingdom participated in the panel discussion.
Q5. What was the main focus of the panel discussion moderated by Dr. Aljadhey?
A5. The panel focused on drug availability, regulatory authorities’ roles ensuring effectiveness and safety, and solutions to enhance patient access while balancing availability and safety.
Q6. What major global health event did the summit discuss lessons from?
A6. The summit discussed lessons learned from the COVID-19 pandemic and future preparedness for potential global health emergencies.
Q7. What is the ICMRA?
A7. The ICMRA is a global alliance of 34 medicines regulatory agencies established in 2012 to enhance international cooperation and address drug safety challenges.
Q8. Which Saudi government agency originally reported on this summit?
A8. The Saudi Press Agency (SPA), the Kingdom’s official news body, originally reported on the SFDA’s participation in the ICMRA summit.
Q9. How does this participation benefit the SFDA?
A9. It strengthens the SFDA’s international role, enhances its standing among peer agencies, and promotes a global approach to anticipating future public health challenges.
Q10. What is a key role of regulatory authorities discussed at the summit?
A10. Authorities discussed their roles in ensuring the effectiveness and safety of medicines and balancing drug availability with safety standards.
Q11. Does this event support Saudi Arabia’s long-term national strategy?
A11. Yes, it directly supports Vision 2030 by enhancing the quality of life, building a vibrant society, and fostering a resilient health sector.
Q12. What is the official name of Japan’s regulatory agency mentioned?
A12. Japan’s regulatory agency is called the Pharmaceuticals and Medical Devices Agency (PMDA), led by CEO Dr. Yasuhiro Fujiwara.
Q13. What advanced topic did summit panels cover regarding future health emergencies?
A13. Panels covered future preparedness for potential global health emergencies, building on the experience gained from the COVID-19 pandemic.
Q14. How many countries are members of the ICMRA?
A14. The ICMRA is a global alliance of 34 medicines regulatory agencies working to enhance international cooperation and regulatory systems.
Q15. What is the SFDA’s role in Saudi Arabia?
A15. The SFDA is the Saudi government authority responsible for regulating food, drugs, and medical devices to ensure public health and safety.
Q16. Which country hosted the 2024 ICMRA annual summit?
A16. Brazil hosted the 2024 ICMRA annual summit, which took place in its capital city, Brasília.
Q17. Did the summit include only drug agencies from specific regions?
A17. No, the ICMRA includes regulatory agencies from all over the world, including the United Kingdom, Japan, Australia, Brazil, and Saudi Arabia.
Q18. What is one key outcome of the SFDA’s participation in global forums?
A18. It promotes a global approach to developing solutions for public health and positions Saudi Arabia as a key partner in international health regulation.
Q19. Is the SFDA a member of the ICMRA?
A19. Yes, the SFDA is a member of the ICMRA, and its CEO’s leadership role at the summit demonstrates its active engagement in the coalition.
Q20. How does the SFDA’s work align with improving patient care?
A20. By ensuring drug safety and effectiveness and working to enhance patient access to medicines, the SFDA directly contributes to improving public health outcomes in Saudi Arabia.
Reader Feedback
We value your thoughts. Please share your feedback on this article.
Your feedback helps us improve our coverage.